|Bid||4.04 x 1000|
|Ask||5.10 x 1300|
|Day's Range||5.04 - 5.18|
|52 Week Range||4.19 - 6.99|
|Beta (5Y Monthly)||0.14|
|PE Ratio (TTM)||N/A|
|Earnings Date||Feb 23, 2020 - Feb 27, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||9.75|
Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company with a focus on hospital acute care, today announced the launch of Caldolor® (ibuprofen) Injection in a ready-to-use bag that may be administered without dilution for pain relief. This launch follows FDA approval in 2019 of the product's new delivery method.
Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) announced today that it will hold an update call to discuss recent developments and plans for the Company's Caldolor® and RediTrexTM brands after the market closes on Tuesday, January 7, 2020. Cumberland will also give 2020 financial guidance during the call. A conference call and live Internet webcast will be held on Tuesday, January 7, at 4:30 p.m. Eastern Time to discuss the results.
With the first-quarter round of 13F filings behind us it is time to take a look at the stocks in which some of the best money managers in the world preferred to invest or sell heading into the second quarter. One of these stocks was Cumberland Pharmaceuticals, Inc. (NASDAQ:CPIX). Cumberland Pharmaceuticals, Inc. (NASDAQ:CPIX) shares haven't […]
Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company, today announced that it has received approval from the U.S. Food and Drug Administration (FDA) for RediTrex™, its new line of methotrexate products.
Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a U.S. specialty pharmaceutical company announces a new online publication in Drugs - Real World Outcomes, detailing the positive clinical outcomes that resulted from treating multiple infection types with Vibativ®, including complicated skin and skin structure infections (cSSSI), bone and joint infections, bacteremia and endocarditis, and lower respiratory tract infections (LRTI).
NASHVILLE, Tenn. , Nov. 12, 2019 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) , a specialty pharmaceutical company focused on hospital acute care and gastroenterology today announced ...
Cumberland Pharmaceuticals (CPIX) closed at $5.56 in the latest trading session, marking a -0.18% move from the prior day.
Cumberland (CPIX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
NASHVILLE, Tenn. , Nov. 5, 2019 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) announced today that it will release third quarter 2019 financial results after the market closes on Tuesday, ...
Cumberland Pharmaceuticals (CPIX) closed at $5.34 in the latest trading session, marking a +0.75% move from the prior day.
NASHVILLE, Tenn., Oct. 15, 2019 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (CPIX), a U.S. specialty pharmaceutical company announces a new publication in Infectious Diseases and Therapy, showing numerically superior cure rates of telavancin compared to vancomycin within a subset of patients who were enrolled in phase 3 ATTAIN trials and had hospital-acquired pneumonia caused by bacteria with low susceptibility to vancomycin. Cumberland manufactures and distributes telavancin under the brand name Vibativ®. Vibativ® (telavancin) is a patented, FDA approved anti-infective for the treatment of certain serious bacterial infections including hospital-acquired and ventilator-associated bacterial pneumonia.
NASHVILLE, Tenn., Sept. 24, 2019 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (CPIX), a specialty pharmaceutical company, today announced FDA Orphan Drug Grant funding for a new Phase II clinical program. The Company has initiated the clinical development of ifetroban for the treatment of cardiomyopathy associated with Duchenne Muscular Dystrophy (DMD). Based on pre-clinical findings, the U.S. Food and Drug Administration (FDA) has cleared Cumberland's application to study ifetroban in DMD patients, 7 years of age and older. In addition, Cumberland has been awarded just over $1 million in funding from the FDA through their Orphan Drug Grant program to support a Phase II DMD clinical study.
Cumberland (CPIX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank 1 (Strong Buy).
Theravance's (TBPH) investigational JAK inhibitor TD-8236 demonstrates favorable results from a phase I study for treating inflammatory lung diseases.